29 August 2017
Clifford Chance advises CSL Limited on the US$352 million acquisition of a blood product manufacturer in China
Leading law firm Clifford Chance has advised the Hong Kong subsidiary of CSL Limited, a global blood and plasma-derived product manufacturer based in Australia, on the acquisition of an 80% equity stake in Ruide, a PRC domestic blood product manufacturer, at a purchase price of US$352 million. The target business includes a manufacturing plant located in Wuhan, four existing plasma stations, and approximately 300 employees.
Lead partner on this matter was Emma Davies in Hong Kong, supported by Shanghai counsel Yang Yi. The firm's Beijing and Washington teams also contributed, including Yue Zheng, Megan Gordon, Ling Ho and Richard Blewett.
Clifford Chance's healthcare and life sciences team has advised in the past year on Pfizer's acquisition of Treerly, one of China's top health and food supplement product businesses, and Biostime's acquisition and restructuring of Swisse Wellness, a leading Australian adult care and nutrition company.